Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells $950,176.32 in Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 105,108 shares of Evolus stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $9.04, for a total transaction of $950,176.32. Following the completion of the sale, the insider owned 499,592 shares of the company’s stock, valued at approximately $4,516,311.68. The trade was a 17.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Evolus Stock Performance

Shares of EOLS stock traded up $0.25 during trading on Friday, hitting $9.30. The company had a trading volume of 684,831 shares, compared to its average volume of 1,087,866. The firm has a market capitalization of $614.26 million, a P/E ratio of -17.88 and a beta of 1.42. Evolus, Inc. has a one year low of $3.86 and a one year high of $9.31. The stock’s 50-day moving average price is $7.26 and its 200 day moving average price is $6.08.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Evolus in a research report on Tuesday, August 25th. Wall Street Zen raised shares of Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Finally, BTIG Research reissued a “buy” rating and issued a $13.00 target price on shares of Evolus in a report on Wednesday, June 17th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $14.50.

Institutional Investors Weigh In On Evolus

Several institutional investors and hedge funds have recently added to or reduced their stakes in EOLS. Larson Financial Group LLC boosted its holdings in shares of Evolus by 136.6% in the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after purchasing an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Evolus during the 4th quarter worth $34,000. Wexford Capital LP acquired a new position in shares of Evolus during the 3rd quarter worth $37,000. California State Teachers Retirement System lifted its position in shares of Evolus by 79.9% during the 2nd quarter. California State Teachers Retirement System now owns 5,455 shares of the company’s stock worth $38,000 after buying an additional 2,423 shares during the last quarter. Finally, Legal & General Group Plc bought a new stake in shares of Evolus during the 2nd quarter worth $40,000. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.